Definium Therapeutics posts corporate presentation highlighting DT120 ODT Phase 3 program in GAD and MDD
PUBT · 4h ago
Share
Listen to the news
- Definium highlighted DT120 ODT, a single-dose lysergide therapy, as its lead late-stage program in five Phase 3 studies for GAD, MDD.
- Emerge Phase 3 topline data in MDD met the primary endpoint; 8.1-point MADRS improvement over placebo at week 6 (p<0.0001).
- Durability signal extended to week 12; 7.3-point MADRS improvement over placebo (p<0.0001); CGI-S improved by 0.9 at day 2 (p<0.0001).
- Safety update showed no serious adverse events in Emerge through week 12; 99% of AEs were mild-to-moderate; no suicidality signal.
- Balance sheet showed cash, cash equivalents, investments of USD 373.4 million as of March 31, 2026; runway expected into 2028.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Definium Therapeutics Inc. published the original content used to generate this news brief on June 22, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved